RxDoctor Payments Data

Christopher Puleo, MD

Cardiovascular Disease · Dallas, TXNPI 1942662697

Payments from drug & device makers

$1,725in general payments, 2019–2025

Across 67 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$287
  • Abbott$248
  • Esperion Therapeutics, Inc.$200
  • Abiomed$178
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$176
  • E.r. Squibb & Sons, L.L.C.$149
  • plus $486 from 6 others

What the payments were for

  • Food & beverage$1,39681%
  • Education$32919%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,725 in reported general payments places this provider in the 30th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$250,233
Medicare patients
536
Services billed
1,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$112,889
XareltoRivaroxaban30$33,879
Atorvastatin Calcium125$2,022
Rosuvastatin Calcium79$1,835
Metoprolol Succinate103$1,753
Ezetimibe32$1,047
Valsartan11$906
Amlodipine Besylate113$805
Losartan Potassium67$752
Nifedipine ErNifedipine16$607
Hydralazine Hcl13$328
Pravastatin Sodium17$327
Furosemide37$325
Lisinopril33$288
Spironolactone29$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$112,889102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →